Antimicrobial Susceptibility Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The antimicrobial susceptibility testing market size is projected to expand from USD 4.72 billion in 2025 and USD 4.97 billion in 2026 to USD 6.57 billion by 2031, registering a CAGR of 5.74% between 2026 to 2031. This report is Segmented by Product (Manual AST, and More), Testing Type (Antibacterial, Antifungal, and More), Application (Clinical Diagnostics, and More), End User (Hospital Laboratories, Reference Laboratories, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Antimicrobial Susceptibility Testing Market Trends and Insights

Escalating Global Antimicrobial Resistance Burden

The 2024 Global Burden of Disease study attributed 1.14 million direct deaths to AMR in 2021 and warned that cumulative mortality could hit 39 million by 2050 if current trends persist. WHO’s 2025 GLASS report logged susceptibility data from 104 countries, up from 87 in 2023, and set a 2030 goal for 80% of members to achieve national diagnostic capacity. In India, intensive-care units reported New Delhi metallo-β-lactamase prevalence above 30%, driving calls for rapid carbapenem-sparing guidance. Europe’s EARS-Net processed 474,364 invasive isolates in 2024 and piloted cefiderocol panels to track resistance to last-resort agents. Yet fewer than 40% of labs in low-income countries can run standardized antimicrobial susceptibility testing (AST), leaving a gap for affordable, low-complexity platforms.

Pharmaceutical and Biotechnology Pipeline Integration of AST

Spero Therapeutics secured FDA approval in September 2024 for tebipenem HBr after Phase 3 trials that used real-time susceptibility data to refine dosing, trimming review timelines. GlaxoSmithKline’s gepotidacin program employed high-throughput AST to map resistance emergence and support 2024 breakpoint proposals to CLSI. FDA guidance issued that same year encourages co-submission of antimicrobials and companion AST assays, enabling synchronized market entry. Contract research organizations reported a 40% increase in AST service requests from biotech clients between 2023 and 2025, as investors demanded pharmacodynamic evidence ahead of Phase 2 funding rounds.

High Upfront Instrumentation Costs and Limited Reimbursement Pathways

Automated AST systems often cost more than USD 100,000, while consumables run USD 15-30 per test; yet, U.S. Medicare reimburses rapid phenotypic AST at only USD 18-22, forcing hospitals to absorb these losses. As of mid-2025, private insurers covered fewer than 50% of claims, limiting uptake outside academic centers. India’s Atmanirbhar Bharat program funded USD 36.5 million for 12 reference labs - barely 0.1% of its estimated 100,000 labs - so most facilities still rely on 18- to 24-hour disk diffusion. A 2024 survey across Sub-Saharan Africa showed 60% of labs lack staff trained in automated AST, even when instruments are donated. Leasing and reagent-rental contracts ease capital expenditures (CAPEX) but shift costs to operational budgets, creating vendor lock-in.

Other drivers and restraints analyzed in the detailed report include:

• Precision Medicine Movement Toward Targeted Antimicrobial Therapy
• Adoption of Rapid Phenotypic AST Platforms for Point-of-Care Decision Making
• Fragmented Global Regulatory and Breakpoint Harmonization Challenges

Segment Analysis

The segment generated the largest share in 2025, when manual procedures still accounted for 51.25% of the antimicrobial susceptibility testing market revenue, due to their low capital requirements. However, automated systems are forecast to advance at a 7.54% CAGR as laboratories chase faster turnaround times and data integration. bioMérieux’s VITEK COMPACT PRO, cleared in 2024, now ships with CLSI AUTO15-compliant autoverification, trimming errors tied to manual transcription. Consumables create sticky revenue; labs spend USD 15-30 per run on panels, media, and controls. Becton Dickinson’s EpiCenter software aggregates outputs across multiple hospitals, delivering stewardship dashboards that extend value beyond the hardware.

Capital constraints and regulatory inertia prolong manual usage, especially in low-income settings where national guidelines do not compel automation. Workforce shortages are shifting opinions: a 2024 cross-Africa survey found that 60% of lab directors viewed automation as a labor multiplier rather than a luxury. Vendors are also bundling identification and susceptibility; Bruker is adapting MALDI-TOF mass spectrometry to flag carbapenemase production, allowing laboratories to justify combined purchases. The dual benefit of speed and reduced hands-on time is expected to accelerate adoption, but success hinges on financing models that ease upfront cost burdens.

Antibacterial panels accounted for 42.43% of 2025 revenue, underscoring their centrality to clinical practice. Nonetheless, antiparasitic assays are the fastest-growing sub-segment, with a 7.66% CAGR, driven by WHO reports of partial artemisinin resistance in six African nations, which demand phenotypic confirmation of kelch13 mutations. Antifungal testing is gaining urgency after Candida auris outbreaks; the CDC counted 3,270 clinical U.S. cases in 2024, fueling hospital adoption of Thermo Fisher’s Sensititre YeastOne system. Automated antifungal panels remain under-penetrated, presenting a white space for vendors. Antiviral AST remains niche, primarily limited to HIV and influenza surveillance.

Mycobacterial testing operates in a separate regulatory lane through the WHO’s Global Laboratory Initiative, relying on MGIT liquid culture and requiring biosafety infrastructure that is often absent in many local labs. The market also lacks integrated molecular-plus-phenotypic platforms for malaria and other parasites, opening development opportunities funded by BARDA and the Wellcome Trust. Collectively, these trends diversify revenue streams away from mature antibacterial offerings.

Complete Report Scope:

• By Product
  • Manual AST
    • MIC Strips
    • Susceptibility Plates
    • Disk Diffusion Kits
    • Others
  • Automated AST Instruments
    • Semi-Automated Systems
    • Fully Automated Systems
  • Consumables and Reagents
  • Software and Services
• By Testing Type
  • Antibacterial
  • Antifungal
  • Antiparasitic
  • Antiviral AST
  • Others
• By Application
  • Clinical Diagnostics
  • Drug Discovery and Development
  • Epidemiology and Surveillance
  • Veterinary Applications
  • Environmental Monitoring
• By End User
  • Hospital Laboratories
  • Reference Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations (CROs)
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • Middle East And Africa
    • GCC
    • South Africa
    • Rest Of Middle East And Africa
  • South America
    • Brazil
    • Argentina
    • Rest Of South America

Geography Analysis

North America accounted for 42.95% of 2025 revenue, driven by CDC efforts to digitize test orders and results, as well as CPT codes that recognize rapid phenotypic AST. Still, reimbursement averaging USD 20 per test lags full cost recovery, limiting adoption to tertiary centers. Canada is piloting centralized provincial labs to serve remote regions, but differing reimbursement rules are slowing the national rollout. BARDA’s 2024 grant to Selux Diagnostics underlines the U.S. federal commitment to sub-4-hour sepsis testing.

Europe benefits from EUCAST’s annually refreshed breakpoints - version 15.0 added eight organism-drug pairs in 2025 - and from EARS-Net surveillance, which covers 474,364 isolates. EMA rules now compel veterinary AST before prescribing the highest-priority antimicrobials, widening the customer base. Nonetheless, reimbursement disparities persist; Germany reimburses rapid AST under DRG, while southern Europe lacks dedicated codes. DARWIN EU real-world evidence supports post-market surveillance but has yet to harmonize payment models.

The Asia-Pacific region is the fastest-growing, forecast to grow at a 6.43% CAGR through 2031. India’s government allocated USD 36.5 million for 12 advanced microbiology centers, and China has integrated AST into provincial AMR surveillance. Japan’s universal coverage eases adoption, though hospital consolidation is shifting volumes to central labs. South Korea introduced tiered reimbursement in 2024 that pays more for rapid AST, aligning financial incentives with stewardship goals. However, rural labs still face staff shortages, echoing challenges seen in less developed regions. National AMR action plans in select emerging markets create smaller but notable growth pockets.

List of Companies Covered in this Report:

• Accelerate Diagnostics, Inc.
• Alifax Srl
• Beckton Dickinson
• bioMérieux
• Bruker
• Creative Diagnostics
• Danaher
• HiMedia Laboratories
• Liofilchem S.r.l.
• Luminex
• Mast Group Ltd.
• Merck
• QIAGEN
• Resistell
• Seegene
• T2 Biosystems, Inc.
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support